Recent advances in the field of syphilis serology have significantly improved the accuracy and efficiency of syphilis screening and diagnostic approaches. The traditional syphilis screening algorithm involves the use of non-treponemal tests such as syphilis diagnosis and control. The commonly accepted syphilis screening algorithm is screening with a non-treponemal test, such as the rapid plasma reagin (RPR) test or the treponemal anti-gp15 and anti-gp116 tests. However, recent studies have demonstrated that a reverse screening sequence using an initial rapid treponemal test followed by a non-treponemal test can improve the detection of syphilis cases.

In a survey of STIs among men who have sex with men (MSM) in Jamaica, syphilis serologic testing is currently conducted using an initial rapid treponemal test followed by a non-treponemal test for reactive sera. Discordant sera that are Bioline-positive and TRUST-negative, or sera with TRUST titres < 8 undergo supplemental testing by TP-PA. SD Bioline was previously validated in the field and reference laboratory in Jamaica and is 95.2% sensitive and 93.5% specific compared to TP-PA. Here we report the results from sera obtained from 135 MSMs in Kingston between December 2010 and February 2011.

Among 135 sera evaluated using the reverse syphilis screening sequence, 15 (9.6%) had a positive rapid treponemal test. Among these 13 reactive sera, 6 (46.2%) were nonreactive with TRUST. All discordant sera were also reactive by TP-PA, indicating that initial rapid testing did not produce false-positives in this setting. The proportion of discordant syphilis test results was similar among HIV+ and HIV- men. The prevalence of primary syphilis detected by concordant positive treponemal and non-treponemal tests in this survey was 5.2%, compared to 5.3% in a previous survey conducted in this population in 2007–2008.

The prevalence of primary syphilis among MSM in Kingston has not changed since the previous survey. In the current survey using the reverse screening sequence, nearly half of sera that were reactive with the treponemal test produced discordant results with the non-treponemal test. Such results are consistent with previous syphilis infection, treated or untreated, or early primary syphilis in which non-treponemal antibodies have yet to develop. Distinguishing these possibilities requires detailed history and clinical assessment in addition to serologic test results.

Recently, automation has been introduced whereby serological screening using treponemal tests has resulted in reduced labour time and removal of the subjectivity associated with the traditional testing algorithm. The objective of this study was to compare the performance characteristics of two FDA approved automated tests, the BioRad BioPlex 2200 Syphilis IgG and the DiaSorin LIAISON treponemal assays, with known predicate tests. The BioPlex 2200 syphilis IgG is a multiplex test that utilises three analytes (15-, 17-, & 47-kDa) to detect specific IgG antibodies, whereas the LIAISON treponemal assay uses only one analyte (17 kDa) in a single step sandwich method to detect both syphilis IgG and IgM antibodies.

Methods A total of 1086 commercially obtained sera tested in this study consisted of: 450 from pregnant women, 409 from HIV positive individuals, and 111 from known syphilis patients of various disease stages. Characterised syphilis samples (n=140) were also obtained from the CDC serum repository. All samples were screened by the BioPlex IgG, LIAISON, RPR and TP-PA tests. Any indeterminate results were repeated at least once.

Results Of the 1086 samples tested, the syphilis reactivities were the following: 551 (50.7%) by BioPlex IgG, 528 (48.6%) by LIAISON, and 509 (46.9%) by TP-PA. The sensitivity and specificity when compared to TP-PA for LIAISON was 98.8% and 90.5% respectively. The BioPlex IgG sensitivity and specificity when compared to TP-PA was 85.1% and 50% respectively. Overall, 443 (40.8%) samples were found to be reactive and 450 (41.4%) non reactive to both BioPlex and LIAISON IgG. All three tests agreed on 877 (81%) samples. On the 209 discordant samples TP-PA agreed with LIAISON 85.2% (n=178), BioPlex 7.2% (n=15), but disagreed with both tests 7.7% (n=10).

Conclusion Both tests have high throughput, walk-away capability, and would be useful in low prevalence settings. There was good agreement between the LIAISON and the BioPlex IgG in 898 (82%) samples (Cohen’s k=0.64). The LIAISON had higher sensitivity most likely due to its detection of both IgG and IgM, while the BioPlex detected only IgG antibodies. Both tests show significant promise in the future of syphilis serology.